Posted by greg rizzo on January 19, 2020, at 12:28:15
In reply to Re: Caplyta, posted by undopaminergic on January 19, 2020, at 8:40:24
Thought was interesting read about on many other sites. YES-illegal to buy the musrooms but not illegal to buy a 'grow kit.'
_______________________________________________
INTERESTING 'MAGIC MUSROOM' STUDIES FOR TRD DEPRESSION --Staines October 26, 2018
-----------------------------------------------
Magic mushroom drug could be depression breakthrough, says FDA Richard Staines.
The liberty cap mushroom, notoriously used illegally as a psychoactive drug, could be the inspiration for a new therapy for depression according to the US drug regulator. Colorado and a few other states have already decriminalized uhe use of magic mushrooms.Mental health drug specialist COMPASS Pathways said that the FDA has designated the chemical psilocybin, which causes psychoactive effects in those eating magic mushrooms such as Psilocybe semilanceata, as a Breakthrough Therapy in treatment-resistant depression.
The FDA gives the designation to drugs where evidence demonstrates they could be a substantial improvement over available therapies for serious or life-threatening diseases.
Drugs given the designation are hastened through the development process by the FDA, which can grant a faster six-month review if it feels the evidence is still compelling once trials are completed.The company said in a statement that the designation is a significant milestone for psilocybin therapy and psilocybin research, after many years of research by teams in the US, the UK and Switzerland.
The Heffter Research Institute was the first to fund research in this field, and supported early studies at Johns Hopkins University, New York University, and Harbor-UCLA Medical Center.
In the UK, the Medical Research Council backed the proof-of-concept study of psilocybin for treatment-resistant depression at Imperial College London.
COMPASS is now running the first large-scale psilocybin therapy clinical trial for treatment-resistant depression, which will take place in Europe and North America over the next year or so.
The company said treatment-resistant depression affects approximately 100 million people around the world.The FDAs decision could prove a bureaucratic headache as psilocybin is deemed a highly illegal schedule 1 drug in the US, with a high potential for abuse and no currently accepted medical use but successful studies could change their approval decision
George Goldsmith, executive chairman, COMPASS Pathways, said: This is great news for patients. We are excited to be taking this work forward with our clinical trial on psilocybin therapy for treatment-resistant depression. The FDA will be working closely with us to expedite the development process and increase the chances of getting this treatment to people suffering with depression as quickly as possible.
poster:greg rizzo
thread:1108054
URL: http://www.dr-bob.org/babble/20200104/msgs/1108068.html